Benzinga - Feed Your Mind.

Benzinga Professional.

Free Streaming News

ARIA 16.77 -0.08 / Ariad Pharmaceuticals, Inc. FDA

Wednesday, March 21, 2012

Morning Social Media Outlook for Wednesday March 21 (SABA, KKD, TRGT, ARIA) (AAPL, AMZN, ARIA, BAC, Earnings, GS, KKD, Long Ideas, News, ORCL, SABA, TRGT, Guidance, Short Ideas, FDA, Movers, Tech, Trading Ideas / Wed, 11:13am)
UPDATE: Merck and ARIAD Pharmaceuticals Provide Update on FDA Advisory Committee Vote; Voted 13 To 1 Against The Use of Ridaforolimus (ARIA, MRK, News, FDA / Wed, 07:52am)

Wednesday, February 15, 2012

ARIAD Announces Issuance of Key U.S. Patent on Ponatinib (ARIA, News, FDA / Wed, 08:35am)

Monday, December 12, 2011

ARIAD Announces Preliminary Data from Pivotal Pace Trial of Ponatinib, Its Investigational pan-BCR-ABL Inhibitor (ARIA, News, FDA / Mon, 07:57am)

Friday, November 18, 2011

FDA Approves Erwinaze To Treat A Form Of Leukemia (ARIA, BMY, GSK, IBB, News, FDA / Fri, 10:34am)

Thursday, November 17, 2011

ARIAD Announces Interim Safety and Efficacy Data from Pivotal Ponatinib PACE Trial to Be Presented (ARIA, News, FDA / Thu, 08:36am)

Wednesday, October 05, 2011

FDA Accepts New Drug Application Filing for Ridaforolimus, Investigational mTOR Inhibitor (ARIA, MRK, News, FDA / Wed, 07:35am)

Monday, September 26, 2011

ARIAD Announces Long-Term Follow Up of Patients with Drug-Resistant CML Treated with Ponatinib in Phase 1 Trial (ARIA, News, FDA / Mon, 07:35am)

Wednesday, September 21, 2011

ARIAD Announces Start of Enrollment in Phase 1/2 Clinical Trial of Oral AP26113, an Investigational Dual Inhibitor of ALK and EGFR in Patients with Lung Cancer (ARIA, News, FDA / Wed, 07:36am)

Thursday, August 18, 2011

Merck and ARIAD Announce European Medicines Agency Accepts Marketing Authorization Application for Ridaforolimus (ARIA, MRK, News, FDA / Thu, 07:32am)

Monday, August 01, 2011

Monday, June 06, 2011

Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting (ARIA, MRK, News, FDA / Mon, 07:31am)

Friday, June 03, 2011

ARIAD Announces Initial Clinical Data on Ponatinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (ARIA, News, FDA / Fri, 07:36am)

Wednesday, April 20, 2011

REGENX BioSciences Licenses ARGENT Gene Regulation Technology From ARIAD Pharmaceuticals, Inc. (ARIA, News, FDA / Wed, 07:57am)
ARIAD Announces Three Exclusive Out-License Agreements to Develop and Commercialize Its ARGENT Cell-Signaling Regulation Technology (ARIA, News, FDA / Wed, 07:37am)

Tuesday, April 05, 2011

ARIAD Presents New Preclinical Data on Ponatinib in Solid Tumors, Demonstrating Inhibition of All FGF Receptor Kinases (ARIA, News, FDA / Tue, 07:36am)

Monday, March 28, 2011

ARIAD And MolecularMD Announce Collaboration for a Companion Diagnostic Test for The T315I BCR-ABL Mutation in Patients With CML (ARIA, News, FDA / Mon, 07:40am)

Wednesday, July 14, 2010

10 Firms Expecting Clinical Trial Results (ARIA, AZN, DNDN, MRK, News, FDA, Markets / Wed, 07:14am)

From Benzinga's Newsdesk

Realtime News With Pro

05:22 AM Koesterich Bullish On Dividend ETFs (HDV, DVYE, DVY)
1:21 AM Benzinga's M&A Chatter for Friday May 25, 2012
8:54 PM S&P 500 Futures at 1324.95, +0.76%
12:47 PM Benzinga's Microcap Movers for Friday May 25, 2012
08:37 AM Earnings Expectations for the Week of May 28 (JOY, SAI, TIVO)
08:05 AM Barron's Recap (5/26/12): The Top 50 Annuities, and Tech Firms Hoard Cash
04:52 PM German Solar Power Plants Produce 50% of the Nation's Electric Energy On Saturday
11:50 AM Research in Motion to Eliminate 2,000 Jobs -Globe and Mail
07:55 PM Klafter Olsen & Lesser Files Class Action against Facebook
7:17 PM Amarin Patent 598 to Be Announced as Officially Issued on May 29
05:05 PM Rite Aid Names John T. Standley Board Chairman
4:45 PM Quest Software Spokesperson is Not Commenting on Report of Deal with Dell as Early as This Weekend
4:43 PM DepoMed Files $100M Mixed Securities Shelf
04:37 PM Albemarle to Increase Ibuprofen Prices
04:34 PM Tranzyme Announces Data Show ULISES 008 Did Not Meet Primary and Secondary Endpoints

Store Professional

Latest from Premium

Brain Trust

Options in Portfolio Allocation:...

Michael Thomsett

More from Michael Thomsett:

Orbitz Worldwide: Its Symbol Says...

Ted Allrich

More from Ted Allrich:

Are Taxes Too Low in the USA?

Barbara Friedberg

More from Barbara Friedberg:

Will the New York Times' ever is...

William K. Black

More from William K. Black:

The Real Deal on Wall Street: 5...

Brian Sozzi

More from Brian Sozzi:

The Facebook IPO: What's Not to...

Michael Prus

More from Michael Prus:

DOW Reversal Predicted by the...

Stephen Bigalow

More from Stephen Bigalow:

Will The Real Housing Market Up?...

Logan Mohtashami

More from Logan Mohtashami:

Financial Careers and Career - of...

George Mentz

More from George Mentz:

Adapting for Traders

Adrienne Toghraie

More from Adrienne Toghraie:

iPad Future Growth

Daniel Ho

More from Daniel Ho:

Insider Sentiment is Neutral to...

Nejat Seyhun

More from Nejat Seyhun:

7 Deadly Sins of Investing: Don't...

Jay Peroni

More from Jay Peroni: